



**The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
February 4, 2020**

Therapeutic Class	Drug Name	DURB Recommendations
Sickle Cell Anemia Treatments		
	<i>Adakveo (Intravenous) Injection</i>	NP/PA (for coverage on the PADL)
	<i>Oxbryta (Oral) Tablet</i>	NP/PA

DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers' Administered Drug List